Great Point Partners’s Milestone Pharmaceuticals MIST Stock Holding History

Great Point Partners’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-674,656	Closed	-$6.2M	–	49
2022 Q3	$6.2M	Buy	+674,656	New	+$5.12M	1.49%	24

Other funds holding MIST

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Great Point Partners's MIST Position: Q4 2022 in Review

Great Point Partners sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 674,656 shares — an estimated $6.2M sold.

Great Point Partners first reported a position in MIST in Q3 2022 and held it in 1 quarter. The position peaked at $6.2M in Q3 2022. 55 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

Great Point Partners reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Great Point Partners sold 674,656 Milestone Pharmaceuticals shares in Q4 2022, an estimated $6.2M.
Great Point Partners first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Great Point Partners's Milestone Pharmaceuticals position peaked at $6.2M in Q3 2022.
55 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.